Share on StockTwits

NxStage Medical (NASDAQ:NXTM) President Joseph E. Turk, Jr. unloaded 1,500 shares of the stock in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $14.00, for a total transaction of $21,000.00. Following the sale, the president now directly owns 127,947 shares in the company, valued at approximately $1,791,258. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Separately, analysts at Canaccord Genuity reiterated a “buy” rating on shares of NxStage Medical in a research note on Friday, May 9th. They now have a $19.00 price target on the stock, down previously from $21.00. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $16.83.

Shares of NxStage Medical (NASDAQ:NXTM) opened at 13.89 on Friday. NxStage Medical has a 52-week low of $8.77 and a 52-week high of $15.00. The stock has a 50-day moving average of $13.20 and a 200-day moving average of $12.50. The company’s market cap is $853.1 million.

NxStage Medical (NASDAQ:NXTM) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.11) by $0.02. The company had revenue of $72.20 million for the quarter, compared to the consensus estimate of $69.44 million. During the same quarter last year, the company posted ($0.08) earnings per share. NxStage Medical’s revenue was up 17.2% compared to the same quarter last year. On average, analysts predict that NxStage Medical will post $-0.40 earnings per share for the current fiscal year.

NxStage Medical, Inc (NASDAQ:NXTM) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.